Skip to main
SXTP

SXTP Stock Forecast & Price Target

SXTP Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

60 Degrees Pharmaceuticals Inc has demonstrated impressive financial growth, reporting a 140% increase in net product revenues, reaching $607.6k for FY24, with Q3 FY25 showcasing an even more remarkable 223% year-over-year increase to $438 thousand. The consistent growth in ARAKODA deliveries, which rose by 14% to 1,505 boxes in Q3 FY25, underscores the product's market traction and demand. Additionally, the potential for tafenoquine's combination use due to its favorable safety profile presents further opportunities for diversification and commercialization, enhancing the company's long-term growth prospects.

Bears say

60 Degrees Pharmaceuticals Inc's stock faces a negative outlook primarily due to its significant cash burn, influenced by the developmental stage of its programs and uncertainty regarding collaborative revenue from partners. The company reported a gross loss of approximately $9,000 in Q3 FY24, attributed to a one-time inventory write-off, which sharply contrasts with the prior gross profit of $36,000, indicating fundamental challenges in maintaining profitability. Additionally, uncertainties surrounding regulatory approvals, potential dilution from future financing needs, and the commercial risks associated with diminishing market share and treatment efficacy further exacerbate concerns regarding the company's financial stability and growth prospects.

SXTP has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 60 Degrees Pharmaceuticals Inc (SXTP) Forecast

Analysts have given SXTP a Strong Buy based on their latest research and market trends.

According to 2 analysts, SXTP has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

60 Degrees Pharmaceuticals Inc (SXTP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.